Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial

• Published in: Circulation (New York, N.Y.) Vol. 143; no. 25; pp. 2418 - 2427
• Main Authors: Pawade, Tania A., Doris, Mhairi K., Bing, Rong, White, Audrey C., Forsyth, Laura, Evans, Emily, Graham, Catriona, Williams, Michelle C., van Beek, Edwin J.R., Fletcher, Alison, Adamson, Philip D., Andrews, Jack P.M., Cartlidge, Timothy R.G., Jenkins, William S.A., Syed, Maaz, Fujisawa, Takeshi, Lucatelli, Christophe, Fraser, William, Ralston, Stuart H., Boon, Nicholas, Prendergast, Bernard, Newby, David E., Dweck, Marc R.
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 22.06.2021
• Subjects: Aged; Aged, 80 and over; Alendronate - therapeutic use; Aortic Valve Stenosis - diagnostic imaging; Aortic Valve Stenosis - drug therapy; Aortic Valve Stenosis - metabolism; Bone Density Conservation Agents - therapeutic use; Denosumab - therapeutic use; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Original s; Positron Emission Tomography Computed Tomography; Treatment Outcome; Vascular Calcification - diagnostic imaging; Vascular Calcification - drug therapy; Vascular Calcification - metabolism; alendronate; computed tomography, X-ray; aortic stenosis; denosumab; calcium signaling

Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with preclinical and observational studies suggesting that bone turnover and osteoblastic differentiation of valvular interstitial cells are important contributory mechanisms. We aimed to establish whether inhi...